These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20732446)

  • 1. The MPTP marmoset model of parkinsonism: a multi-purpose non-human primate model for neurodegenerative diseases.
    Philippens IH; 't Hart BA; Torres G
    Drug Discov Today; 2010 Dec; 15(23-24):985-90. PubMed ID: 20732446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
    van Vliet SA; Blezer EL; Jongsma MJ; Vanwersch RA; Olivier B; Philippens IH
    Brain Res; 2008 Jan; 1189():219-28. PubMed ID: 18076869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23.
    Willis GL; Robertson AD
    Pharmacol Biochem Behav; 2005 Jan; 80(1):9-26. PubMed ID: 15652376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Selective stimulations and lesions of the rat brain nuclei as the models for research of the human sleep pathology mechanisms].
    Šaponjić J
    Glas Srp Akad Nauka Med; 2011; (51):85-97. PubMed ID: 22165729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marmoset monkey models of Parkinson's disease: which model, when and why?
    Eslamboli A
    Brain Res Bull; 2005 Dec; 68(3):140-9. PubMed ID: 16325013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism.
    Halliday G; Herrero MT; Murphy K; McCann H; Ros-Bernal F; Barcia C; Mori H; Blesa FJ; Obeso JA
    Mov Disord; 2009 Jul; 24(10):1519-23. PubMed ID: 19526568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of MPTP toxicity.
    Przedborski S; Jackson-Lewis V
    Mov Disord; 1998; 13 Suppl 1():35-8. PubMed ID: 9613716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy parkinsonism.
    Park HJ; Bang G; Lee BR; Kim HO; Lee PH
    Cell Transplant; 2011; 20(6):827-35. PubMed ID: 21054946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spinal cord and parkinsonism: neuromorphological evidences in humans and experimental studies.
    Vivacqua G; Casini A; Vaccaro R; Salvi EP; Pasquali L; Fornai F; Yu S; D'Este L
    J Chem Neuroanat; 2011 Dec; 42(4):327-40. PubMed ID: 21392570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model.
    Barraud Q; Lambrecq V; Forni C; McGuire S; Hill M; Bioulac B; Balzamo E; Bezard E; Tison F; Ghorayeb I
    Exp Neurol; 2009 Oct; 219(2):574-82. PubMed ID: 19635479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.
    Fox SH; Brotchie JM
    Prog Brain Res; 2010; 184():133-57. PubMed ID: 20887873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic zebrafish model of neurodegeneration.
    Tomasiewicz HG; Flaherty DB; Soria JP; Wood JG
    J Neurosci Res; 2002 Dec; 70(6):734-45. PubMed ID: 12444595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights on the pathogenesis of neurodegenerative disorders.
    Piccoli F; La Bella V; Guarneri R
    Acta Neurol (Napoli); 1992; 14(4-6):455-68. PubMed ID: 1338180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism.
    Duka T; Rusnak M; Drolet RE; Duka V; Wersinger C; Goudreau JL; Sidhu A
    FASEB J; 2006 Nov; 20(13):2302-12. PubMed ID: 17077307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular pathways leading to neuronal dysfunction and degeneration.
    Kazantsev AG
    Drug News Perspect; 2007 Oct; 20(8):501-9. PubMed ID: 18080037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
    Beal MF
    Ann Neurol; 1992 Feb; 31(2):119-30. PubMed ID: 1349466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration.
    Uversky VN
    Cell Tissue Res; 2004 Oct; 318(1):225-41. PubMed ID: 15258850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
    Watanabe Y; Himeda T; Araki T
    Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.